You are viewing: Canada Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Canada Plasma Fractionation Market was valued at $1508.2 Million in 2026 and projected to reach to $2120.7 Million by 2031, representing a compound annual growth rate of 7.1%. Canada's plasma fractionation market is positioned for steady growth through 2031, supported by an aging population requiring specialized immunological and hematological treatments.

Canada Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Canada Plasma Fractionation Market Trends and Insights

  • Canada's healthcare infrastructure and aging population are driving demand for immunoglobulins, clotting factors, and albumin products essential for treating immunodeficiency disorders, hemophilia, and critical care conditions.
  • The Canadian market benefits from strong regulatory oversight, established plasma collection networks, and increasing adoption of advanced fractionation technologies. Canada's plasma fractionation sector is characterized by a mix of domestic and international plasma protein manufacturers serving both Canadian patients and export markets.
  • Canada's commitment to self-sufficiency in plasma-derived therapeutics, combined with rising prevalence of rare bleeding disorders and immunological conditions, supports sustained market growth through 2031.
  • Investment in plasma collection infrastructure and manufacturing capacity expansion across Canada reflects confidence in long-term market fundamentals..

Key Market Statistics

  • CAGR (2026-2031) 7.1% CAGR
  • Market Size, 2026 ~USD 1508.2 Million
  • Forecast, 2031 ~USD 2120.7 Million
  • Country Canada

Canada Plasma Fractionation Market Overview

Market Valuation Growth :

Canada's plasma fractionation market is valued at USD 1,508.2 million in 2026 and is projected to reach USD 2,120.7 million by 2031, demonstrating robust expansion driven by healthcare demand.

Aging Population Dynamics :

Canada's demographic shift toward an older population is significantly increasing demand for plasma-derived therapies, particularly immunoglobulins and clotting factors for age-related conditions.

Healthcare Infrastructure Advantage :

Canada's advanced healthcare system and universal coverage model support consistent demand for critical plasma fractionation products across hospitals, clinics, and specialty treatment centers.

Therapeutic Product Focus :

Key products driving the Canadian market include immunoglobulins for immunodeficiency disorders, clotting factors for hemophilia treatment, and albumin for critical care applications.

Canada Plasma Fractionation Market Dynamics

  • The country's robust healthcare infrastructure and universal coverage system ensure consistent demand for plasma-derived therapies across all provinces.
  • Increasing prevalence of immunodeficiency disorders and hemophilia, combined with rising awareness of plasma fractionation benefits, will drive market expansion.
  • Investment in domestic plasma collection facilities and regulatory support for biopharmaceutical innovation will further strengthen market dynamics.
  • The 7.1% CAGR reflects Canada's commitment to maintaining therapeutic product availability and improving patient outcomes in critical care settings..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Canada's plasma fractionation market reaches USD 1,508.2M in 2026 and grows to USD 2,120.7M by 2031 at a 7.1% CAGR.
      • Canada's aging demographic and rising immunodeficiency disorder prevalence drive sustained demand for plasma-derived therapeutics.
      • Canada's regulatory framework and plasma collection infrastructure support market expansion and domestic self-sufficiency initiatives.
      • Canada's market benefits from both domestic consumption and export opportunities to international healthcare systems.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Canada Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Biopharmaceutical Manufacturers : Manufacturers need Canada-specific market data to develop localized product strategies, optimize supply chain operations, and identify partnership opportunities within the Canadian healthcare system.
      • Healthcare Providers & Hospital Networks : Canadian hospitals and specialty clinics require market insights to forecast plasma fractionation product demand, optimize procurement budgets, and ensure adequate therapeutic inventory for patient care.
      • Investment & Private Equity Firms : Investors evaluating opportunities in Canada's biopharmaceutical sector need detailed market analysis to assess growth potential, competitive positioning, and return on investment in plasma fractionation companies.
      • Regulatory & Policy Advisors : Government agencies, health authorities, and policy consultants use market data to inform healthcare policy decisions, plasma collection strategies, and therapeutic product accessibility initiatives across Canada.
      • Market Research & Consulting Professionals : Analysts and consultants require granular Canadian market data to support client advisory services, competitive benchmarking, and strategic planning for healthcare and pharmaceutical stakeholders.

      Reasons to Buy this Report

      • Country-Specific Market Sizing : Access precise valuation data for Canada's plasma fractionation market with verified 2026-2031 forecasts, enabling accurate budget allocation and investment decisions tailored to the Canadian healthcare landscape.
      • Demographic Insights for Canada : Understand how Canada's aging population directly impacts demand for immunoglobulins, clotting factors, and albumin, with actionable insights for product positioning and market penetration strategies.
      • Regulatory & Healthcare System Analysis : Gain detailed knowledge of Canada's universal healthcare coverage model, provincial regulations, and reimbursement frameworks affecting plasma fractionation product adoption and market dynamics.
      • Competitive Landscape for Canada : Identify key players, market share distribution, and competitive strategies specific to the Canadian market, enabling informed partnership and expansion decisions.
      • Growth Opportunity Identification : Discover high-potential segments within Canada's plasma fractionation market, including emerging therapeutic applications and underserved patient populations for targeted business development.

      Frequently asked questions

      What is the current size of Canada's plasma fractionation market?

      Canada's plasma fractionation market is valued at USD 1,508.2 million in 2026 and is projected to reach USD 2,120.7 million by 2031.

      What is the expected growth rate for Canada's plasma fractionation market?

      Canada's plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2031.

      What factors are driving growth in Canada's plasma fractionation market?

      Canada's market growth is driven by an aging population, increasing prevalence of immunodeficiency and bleeding disorders, strong regulatory oversight, and established plasma collection networks.

      Which plasma-derived products are most in demand in Canada?

      Canada's demand is highest for immunoglobulins, clotting factors, and albumin products used to treat immunodeficiency disorders, hemophilia, and critical care conditions.

      How does Canada's plasma fractionation market compare to North America?

      Canada represents a significant portion of the North American plasma fractionation market, with strong regulatory standards and a commitment to plasma-derived therapeutic self-sufficiency.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status